Compass Pathways (NASDAQ:CMPS – Get Free Report) was upgraded by stock analysts at Evercore from an “in-line” rating to an “outperform” rating in a research report issued to clients and investors on Wednesday. The firm presently has a $21.00 price objective on the stock. Evercore’s price target suggests a potential upside of 53.53% from the stock’s current price.
A number of other equities analysts have also weighed in on the stock. Compass Point set a $25.00 price objective on shares of Compass Pathways in a research report on Tuesday. Morgan Stanley reiterated an “overweight” rating and set a $17.00 target price on shares of Compass Pathways in a research report on Tuesday. Wall Street Zen raised shares of Compass Pathways from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. TD Cowen reaffirmed a “buy” rating on shares of Compass Pathways in a research note on Monday, June 1st. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $20.00 price target on shares of Compass Pathways in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $24.15.
Read Our Latest Stock Analysis on CMPS
Compass Pathways Stock Performance
Compass Pathways (NASDAQ:CMPS – Get Free Report) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.15. As a group, sell-side analysts predict that Compass Pathways will post -1.24 earnings per share for the current year.
Institutional Trading of Compass Pathways
Institutional investors and hedge funds have recently bought and sold shares of the company. EverSource Wealth Advisors LLC boosted its holdings in Compass Pathways by 67.7% in the first quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock worth $26,000 after purchasing an additional 1,920 shares during the period. Persistent Asset Partners Ltd acquired a new stake in shares of Compass Pathways during the 4th quarter worth approximately $38,000. Parallel Advisors LLC boosted its position in Compass Pathways by 8,450.6% during the 1st quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock valued at $40,000 after purchasing an additional 7,183 shares during the period. Advisory Services Network LLC acquired a new stake in Compass Pathways in the third quarter worth $41,000. Finally, North Star Investment Management Corp. boosted its holdings in shares of Compass Pathways by 1,354.0% during the first quarter. North Star Investment Management Corp. now owns 7,517 shares of the company’s stock valued at $42,000 after acquiring an additional 7,000 shares during the period. Institutional investors and hedge funds own 46.19% of the company’s stock.
Compass Pathways Company Profile
Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.
See Also
- Five stocks we like better than Compass Pathways
- These 3 Cash-Flow Stocks Give Investors More Than Just Growth Potential
- Vertex’s Crinetics Deal Balances Growth with Integration Risk
- Stacking Chips: The Hidden Supply Shock Fueling Intel
- Drone Stocks Are Down, But Defense Backlogs Tell a Different Story
Receive News & Ratings for Compass Pathways Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Pathways and related companies with MarketBeat.com's FREE daily email newsletter.
